Redesigning Revenue Management for the Modern Pharma Supply Chain
What a $150M transformation from industry laggard to Supplier of the Year taught me about the intersection of technology, customer relationships, and commercial strategy.
Original thinking from 25+ years operating at the full breadth of the CIO mandate — running mission-critical platforms, transforming commercial operations, and building enterprise AI programs that deliver measurable value.
The technology leader conversations I find most interesting aren't about the next AI model or the next platform. They're about a harder question: how do you run a complex, regulated, mission-critical technology operation — reliably, cost-efficiently, compliantly — while simultaneously building the next generation of capability?
In the pharmaceutical industry, this tension is particularly acute. The systems that manage government pricing, payer contracts, wholesaler inventory, and patient services cannot go down, cannot be out of compliance, and cannot be slow. That operational discipline isn't a constraint on innovation — it's the precondition for it. Organizations trust technology leaders with transformation precisely because they have demonstrated they can run things well first.
After two and a half decades operating at both ends of this spectrum — from 100% audit success across SOX, HIPAA, GxP, and CMS to $1.5B in enterprise AI value — here is what I've learned about the CIO mandate that the conference circuit often misses.
Recent Articles
What a $150M transformation from industry laggard to Supplier of the Year taught me about the intersection of technology, customer relationships, and commercial strategy.
Culture eats strategy for breakfast — and AI strategy is no different. How we built certification, champion networks, and academic partnerships that made adoption a competitive advantage.
The shift from project-based IT delivery to a product operating model is not cosmetic. It changes accountability structures, hiring profiles, governance models, and how business value is measured.
Having led multiple large-scale ERP programs across global pharmaceutical operations, the patterns of success and failure are remarkably consistent — and most have nothing to do with the technology itself.
Patient time-to-fill and refill performance are not just patient experience metrics — they are revenue and market share metrics. The technology opportunity to move the needle is significant and underinvested.
In a regulated pharmaceutical environment, compliance failures are not recoverable events. Here's how to build the controls, governance, and organizational discipline that make 100% audit success a structural outcome — not a heroic effort.
Regular posts on enterprise AI, healthcare technology strategy, and leadership — connecting this site's long-form thinking to ongoing professional dialogue.